Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.78% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.78% | |
| Lower Bollinger Band Touch | Weakness | 0.78% | |
| Bollinger Band Squeeze | Range Contraction | -3.35% | |
| Outside Day | Range Expansion | -3.35% | |
| Bollinger Band Squeeze | Range Contraction | -3.70% |
| Alert | Time |
|---|---|
| 2x Volume Pace | 4 days ago |
| 1.5x Volume Pace | 4 days ago |
| Down 3% | 5 days ago |
| Fell Below Previous Day's Low | 5 days ago |
| Down 2 % | 5 days ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.59 |
| 52 Week Low | 1.0 |
| Average Volume | 19,329 |
| 200-Day Moving Average | 3.85 |
| 50-Day Moving Average | 4.77 |
| 20-Day Moving Average | 5.53 |
| 10-Day Moving Average | 5.37 |
| Average True Range | 0.37 |
| RSI (14) | 48.72 |
| ADX | 13.28 |
| +DI | 18.14 |
| -DI | 23.33 |
| Chandelier Exit (Long, 3 ATRs) | 5.15 |
| Chandelier Exit (Short, 3 ATRs) | 5.63 |
| Upper Bollinger Bands | 5.97 |
| Lower Bollinger Band | 5.09 |
| Percent B (%b) | 0.12 |
| BandWidth | 15.83 |
| MACD Line | 0.11 |
| MACD Signal Line | 0.19 |
| MACD Histogram | -0.0853 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.44 | ||||
| Resistance 3 (R3) | 5.44 | 5.37 | 5.40 | ||
| Resistance 2 (R2) | 5.37 | 5.31 | 5.36 | 5.38 | |
| Resistance 1 (R1) | 5.28 | 5.27 | 5.32 | 5.28 | 5.37 |
| Pivot Point | 5.21 | 5.21 | 5.23 | 5.21 | 5.21 |
| Support 1 (S1) | 5.13 | 5.15 | 5.17 | 5.12 | 5.03 |
| Support 2 (S2) | 5.05 | 5.11 | 5.05 | 5.02 | |
| Support 3 (S3) | 4.97 | 5.05 | 5.00 | ||
| Support 4 (S4) | 4.96 |
